Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The global hematologic malignancies market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026.

Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.

Hematologic Malignancies Market Trends:

The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, therapy and end user.

Breakup by Type:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others
     

Breakup by Therapy:

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others
     

Breakup by End User:

  • Hospitals
  • Diagnostics Centers
  • Research Centers
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Report Coverages:

Report Features Details
Base Year of the Analysis 2020
    Historical Period 2015-2020
Forecast Period 2021-2026
Units US$ Billion
Segment Coverage Type, Therapy, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Customization Scope 10% Free Customization
Report Price and Purchase Option                                     Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Hematologic Malignancies Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Type
    6.1    Leukemia
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Lymphoma
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Multiple Myeloma
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Others
        6.4.1 Market Trends
        6.4.2 Market Forecast
7    Market Breakup by Therapy
    7.1    Chemotherapy
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Radiotherapy
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Immunotherapy
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Stem Cell Transplantation
        7.4.1 Market Trends
        7.4.2 Market Forecast
    7.5    Others
        7.5.1 Market Trends
        7.5.2 Market Forecast
8    Market Breakup by End User
    8.1    Hospitals
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Diagnostics Centers 
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Research Centers
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Others
        8.4.1 Market Trends
        8.4.2 Market Forecast
9    Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia-Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10    SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11    Value Chain Analysis
12    Porters Five Forces Analysis

    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13    Price Analysis
14    Competitive Landscape

    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    AbbVie Inc.
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio
           14.3.1.3 Financials
           14.3.1.4 SWOT Analysis
        14.3.2    AstraZeneca plc
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio
           14.3.2.3 Financials
           14.3.2.4 SWOT Analysis
        14.3.3    Bristol-Myers Squibb Company
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio
           14.3.3.3 Financials
           14.3.3.4 SWOT Analysis
        14.3.4    Eli Lilly and Company
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio
           14.3.4.3 Financials
           14.3.4.4 SWOT Analysis
        14.3.5    F. Hoffmann-La Roche Ltd
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio
           14.3.5.3 Financials
        14.3.6    GlaxoSmithKline plc
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio
           14.3.6.3 Financials
           14.3.6.4 SWOT Analysis
        14.3.7    Johnson & Johnson
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio
           14.3.7.3 Financials
           14.3.7.4 SWOT Analysis
        14.3.8    Merck & Co. Inc
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio
           14.3.8.3 Financials
           14.3.8.4 SWOT Analysis
        14.3.9    Novartis AG
           14.3.9.1 Company Overview
           14.3.9.2 Product Portfolio
           14.3.9.3 Financials
           14.3.9.4 SWOT Analysis
        14.3.10    Pfizer Inc.
           14.3.10.1 Company Overview
           14.3.10.2 Product Portfolio
           14.3.10.3 Financials
           14.3.10.4 SWOT Analysis
        14.3.11    Sanofi S.A.
           14.3.11.1 Company Overview
           14.3.11.2 Product Portfolio
           14.3.11.3 Financials
           14.3.11.4 SWOT Analysis
        14.3.12    Takeda Pharmaceutical Company Limited
           14.3.12.1 Company Overview
           14.3.12.2 Product Portfolio
           14.3.12.3 Financials
           14.3.12.4 SWOT Analysis

List of Figures

Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2020
Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2020
Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2020
Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2020
Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2015 & 2020
Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2015 & 2020
Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2015 & 2020
Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2015 & 2020
Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2015 & 2020
Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2015 & 2020
Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2015 & 2020
Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2015 & 2020
Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2015 & 2020
Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2015 & 2020
Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2020
Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2021-2026
Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2021-2026
Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2021-2026
Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 6: Global: Hematologic Malignancies Market: Competitive Structure
Table 7: Global: Hematologic Malignancies Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2299

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links